Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
On The Record Ka Linde Epub Bud
2ff7e9595c
top of page
bottom of page
Comments